Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial in those with methylthioadenosine phosphorylase (MTAP)-deleted solid tumours ...

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors Provided by GlobeNewswire May 21, 2025, 11:00:00 AM ...

The first-in-human Phase 1a/b clinical trial of GTA182 is an open-label, multicenter study involving dose escalation and dose expansion. The study will enroll patients with MTAP-null solid tumors ...

About 15% of all cancers have co-deletion of both the MTAP and CDKN2A genes, which results in sensitization to MAT2A inhibitors, thus opening a therapeutic window in these cancer types. MAT2A ...

The priority MTAP-deletion solid tumor types for the IDE397 Phase 1/2 monotherapy program are UC and NSCLC. MTAP-deletion has been reported at over 15% in NSCLC and over 25% in UC, ...

The use of Trodelvy in MTAP-deletion UC is investigational, and the safety and efficacy of this use have not been established. A clinical program update on the IDE397 and Trodelvy combination is ...

Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial in those with methylthioadenosine phosphorylase (MTAP)-deleted solid tumours ...